NifuratelAntibacterial, antifungal, and antiprotozoal compound CAS# 4936-47-4 |
- Sulfo-NHS-Biotin
Catalog No.:BCC3576
CAS No.:119616-38-5
- Sulfo-NHS-LC-Biotin
Catalog No.:BCC3578
CAS No.:127062-22-0
- NHS-Biotin
Catalog No.:BCC3577
CAS No.:35013-72-0
- Biotin Hydrazide
Catalog No.:BCC3582
CAS No.:66640-86-6
- NHS-LC-Biotin
Catalog No.:BCC3579
CAS No.:72040-63-2
- Iodoacetyl-LC-Biotin
Catalog No.:BCC3584
CAS No.:93285-75-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 4936-47-4 | SDF | Download SDF |
| PubChem ID | 6507267 | Appearance | Powder |
| Formula | C10H11N3O5S | M.Wt | 285.28 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | NF 113; SAP 113; Methylmercadone | ||
| Solubility | DMSO : 50 mg/mL (175.27 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 5-(methylsulfanylmethyl)-3-[(Z)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one | ||
| SMILES | CSCC1CN(C(=O)O1)N=CC2=CC=C(O2)[N+](=O)[O-] | ||
| Standard InChIKey | SRQKTCXJCCHINN-WCIBSUBMSA-N | ||
| Standard InChI | InChI=1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4- | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Nifuratel(NF 113, SAP 113) is a broad antibacterial spectrum agent, which is used as an antibacterial, antifungal, and antiprotozoal (Trichomonas).
IC50 Value: 0.125-1 μg/mL(MIC, A. vaginae) [1]
Target: Antibacterial; Antiprotozoal
in vitro: In vitro, nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 μg/mL; it is active against G. vaginalis and does not affect lactobacilli [1].
in vivo: Patients were randomized to receive a 2-week course of bismuth subcitrate (8 mg/kg/day, q.d.s.), amoxicillin (50 mg/kg/day, q.d.s.), with either nifuratel (15 mg/kg/day, q.d.s.) or furazolidone (10 mg/kg/day, q.d.s.), plus omeprazole (0.5 mg/kg, once daily) [2].
Toxicity: There were no serious adverse reactions and were no withdrawals due to any side-effects. All of side-effects were self-limiting (dark stools, urine discoloration, blackening of the tongue, and others) [3].
Clinical trial: N/A References: | |||||
Nifuratel Dilution Calculator
Nifuratel Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5053 mL | 17.5266 mL | 35.0533 mL | 70.1066 mL | 87.6332 mL |
| 5 mM | 0.7011 mL | 3.5053 mL | 7.0107 mL | 14.0213 mL | 17.5266 mL |
| 10 mM | 0.3505 mL | 1.7527 mL | 3.5053 mL | 7.0107 mL | 8.7633 mL |
| 50 mM | 0.0701 mL | 0.3505 mL | 0.7011 mL | 1.4021 mL | 1.7527 mL |
| 100 mM | 0.0351 mL | 0.1753 mL | 0.3505 mL | 0.7011 mL | 0.8763 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: 0.125-1 μg/mL(MIC, A. vaginae) [1] Nifuratel appears to have a broad antibacterial spectrum of action and is effective against Chlamydia trachomatis and Mycoplasma spp. as well as fungal infections from Candida spp. in vitro: In vitro, nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 μg/mL; it is active against G. vaginalis and does not affect lactobacilli [1]. in vivo: Patients were randomized to receive a 2-week course of bismuth subcitrate (8 mg/kg/day, q.d.s.), amoxicillin (50 mg/kg/day, q.d.s.), with either nifuratel (15 mg/kg/day, q.d.s.) or furazolidone (10 mg/kg/day, q.d.s.), plus omeprazole (0.5 mg/kg, once daily) [2]. Toxicity: There were no serious adverse reactions and were no withdrawals due to any side-effects. All of side-effects were self-limiting (dark stools, urine discoloration, blackening of the tongue, and others) [3]. Clinical trial: N/A
- Methyl L-pyroglutamate
Catalog No.:BCN7060
CAS No.:4931-66-2
- Savinin
Catalog No.:BCN5602
CAS No.:493-95-8
- α-D-Glucose
Catalog No.:BCC9197
CAS No.:492-62-6
- Kynurenic acid
Catalog No.:BCN2228
CAS No.:492-27-3
- Butin
Catalog No.:BCN4630
CAS No.:492-14-8
- Plathymenin
Catalog No.:BCN6810
CAS No.:492-12-6
- (+)-Sparteine
Catalog No.:BCC9249
CAS No.:492-08-0
- Thermopsidine
Catalog No.:BCN7923
CAS No.:492-02-4
- TCS PIM-1 1
Catalog No.:BCC2447
CAS No.:491871-58-0
- Hemokinin 1 (human)
Catalog No.:BCC5923
CAS No.:491851-53-7
- Biochanin A
Catalog No.:BCN1224
CAS No.:491-80-5
- Iridin
Catalog No.:BCN6868
CAS No.:491-74-7
- Isoammodendrine
Catalog No.:BCN2146
CAS No.:494-15-5
- Nornicotine
Catalog No.:BCN8176
CAS No.:494-97-3
- TC-G 1001
Catalog No.:BCC6316
CAS No.:494191-73-0
- Ginsenoside Rk1
Catalog No.:BCN3552
CAS No.:494753-69-4
- Auraptene
Catalog No.:BCN5603
CAS No.:495-02-3
- Ammijin
Catalog No.:BCN3617
CAS No.:495-30-7
- Nodakenin
Catalog No.:BCN2378
CAS No.:495-31-8
- Nodakenetin
Catalog No.:BCN5604
CAS No.:495-32-9
- Desoxypeganine
Catalog No.:BCN8032
CAS No.:495-59-0
- Tropine isobutyrate
Catalog No.:BCN1923
CAS No.:495-80-7
- Valtropine
Catalog No.:BCN1926
CAS No.:495-82-9
- Tigloyltropeine
Catalog No.:BCN1944
CAS No.:495-83-0
Bacterial vaginosis, Atopobium vaginae and nifuratel.[Pubmed:22082330]
Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40.
As bacterial vaginosis (BV) is a potential cause of obstetric complications and gynecological disorders, there is substantial interest in establishing the most effective treatment. Standard treatment - metronidazole or clindamycin, by either vaginal or oral route is followed by relapses in about 30% of cases, within a month from treatment completion. This inability to prevent recurrences reflects our lack of knowledge on the origins of BV. Atopobium vaginae has been recently reported to be associated with BV in around 80% of the cases and might be involved in the therapeutic failures. This review looks at the potential benefits of Nifuratel against A. vaginae compared to the standard treatments with metronidazole and clindamycin. In vitro, Nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 mug/mL; it is active against G. vaginalis and does not affect lactobacilli. Metronidazole is active against A. vaginae only at very high concentrations (8-256 mug/mL); it is partially active against G. vaginalis and also has no effect on lactobacilli. Clindamycin acts against A. vaginae with an MIC lower than 0.125 mug/mL and is active on G. vaginalis but it also affects lactobacilli, altering the vaginal environment. These observations suggest that Nifuratel is probably the most valid therapeutic agent for BV treatment.
In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?[Pubmed:21321147]
Antimicrob Agents Chemother. 2011 May;55(5):2490-2.
Bacterial vaginosis is characterized by a shift of the physiological flora to a diverse spectrum of bacteria, where Gardnerella vaginalis and Atopobium vaginae are the most important markers. In this study, the antimicrobial activity of Nifuratel against G. vaginalis, A. vaginae, and lactobacilli was compared with that of the two currently used antibiotics metronidazole and clindamycin. Results suggest that Nifuratel has a better spectrum of activity, being highly active against G. vaginalis and A. vaginae without affecting lactobacilli.
High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study.[Pubmed:27435791]
J Obstet Gynaecol Res. 2016 Oct;42(10):1354-1360.
AIM: The efficacy and safety of two Nifuratel dosages for the treatment of aerobic vaginitis (AV) were compared. METHODS: This was a prospective open-label cohort study of patients diagnosed and treated at the Tianjin Third Central Hospital between January 2012 and December 2013. The co-presence of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or/and trichomonal vaginitis (TV; mixed AV) was determined. Patients were randomized to Nifuratel-500 (500 mg Nifuratel, intravaginal, 10 days) or Nifuratel-250 (250 mg Nifuratel, intravaginal, 10 days), and followed-up for three to seven days after treatment completion. Primary and secondary outcomes were recovery rate and adverse events, respectively. RESULTS: The study included 142 patients with AV. Age was not significantly different between the groups (n = 71 each), and disease distribution was identical: 29 (40.85%) simple AV and 42 (59.15%) mixed AV (AV + BV, 42.86 %; AV + VVC, 30.95%; AV + TV, 26.19%). In patients with simple AV, the recovery rate did not differ significantly between the Nifuratel-500 (26/29, 89.66%) and Nifuratel-250 (22/29, 75.86%) groups. In patients with mixed AV, recovery rates were significantly higher in the Nifuratel-500 than in the Nifuratel-250 group (AV + BV, 88.89% vs 50.00 %; AV + VVC, 76.92 % vs 30.77 %; AV + TV, 90.91 % vs 36.36%; all P < 0.05). Only one patient (Nifuratel-500) reported an adverse event (mild anaphylactic reaction). CONCLUSION: Nifuratel 500 mg showed good clinical efficacy for the treatment of AV, particularly mixed AV, and is superior to the 250 mg dosage in the treatment of mixed AV.
